Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Valvular Heart Disease
Interventions
HBCR hands-off, HBCR interactive
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hypertrophic Cardiomyopathy
Interventions
pacemaker implantation, percutaneous transluminal septal ablation (PTSA)
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Self-Centering Guide Catheter Feasibility Study

NCT02639494
Conditions
Aortic Stenosis
Interventions
Self-Centering Guide Catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 110 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

Medtronic CoreValve Evolut R U.S. Clinical Study

NCT02207569
Conditions
Aortic Stenosis
Interventions
CoreValve Evolut R TAVR system
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 18 more
Conditions
Aortic Stenosis
Interventions
TAVR
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
50 Years and older
Enrollment
200 participants
Timeline
2018 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Calcific Aortic Valve Disease
Interventions
Evogliptin, Placebo
Drug
Lead sponsor
REDNVIA Co., Ltd.
Industry
Eligibility
35 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 21 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Active, not recruiting Not applicable Interventional

The JenaValve ALIGN-AR Pivotal Trial

NCT04415047
Conditions
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
Interventions
JenaValve Trilogy Heart Valve System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 25 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vivio AS (Aortic Stenosis) Algorithm Optimization Study

NCT04068402
Conditions
Aortic Stenosis
Interventions
Vivio System
Device
Lead sponsor
Avicena LLC
Industry
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
Conditions
Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Congenital Pulmonary Valve Abnormality
Interventions
Edwards Pericardial Aortic Bioprosthesis Model 11000A
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
5 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypertrophic Cardiomyopathy
Interventions
on-pump intracardiac echocardiography
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional Accepts healthy volunteers

Imaging Histone Deacetylase in the Heart

NCT03549559
Conditions
Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes
Interventions
11C-Martinostat, PET-MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

NCT02413450
Conditions
Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Not listed Not applicable Interventional Results available

JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

NCT02732691
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction
Interventions
JenaValve Pericardial TAVR System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Recruiting No phase listed Observational

VIZ ACCESS HCM - Multi-Site Registry

NCT07103057
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania
Conditions
Aortic Stenosis
Interventions
Transfemoral TAVR, SAVR
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Not listed
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 7 more
Active, not recruiting No phase listed Observational

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

NCT03440697
Conditions
Aortopathies, Thoracic Aortic Aneurysm, Aortic Valve Disease, Thoracic Aortic Disease, Thoracic Aortic Dissection, Thoracic Aortic Rupture, Ascending Aortic Disease, Descending Aortic Disease, Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Marfan Syndrome, Loeys-Dietz Syndrome, Vascular Ehlers-Danlos Syndrome, Shprintzen-Goldberg Syndrome, Turner Syndrome, PHACE Syndrome, Autosomal Recessive Cutis Laxa, Congenital Contractural Arachnodactyly, Arterial Tortuosity Syndrome, Bicuspid Aortic Valve-Associated Aortopathy, Bicuspid Aortic Valve, Familial Thoracic Aortic Aneurysm and Aortic Dissection
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia • Indianapolis, Indiana
Conditions
Hypertrophic Cardiomyopathy
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
Conditions
Aortic Stenosis
Interventions
Medtronic TAV, Edwards TAV
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years to 105 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
Moderate Intensity Exercise Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease

NCT02266251
Conditions
Aortic Valve Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
273,365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina